Cabaletta Bio
CABA
60 hedge funds and large institutions have $183M invested in Cabaletta Bio in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 17 closing their positions.
2,256% more capital invested
Capital invested by funds: $7.76M → $183M (+$175M)
430% more call options, than puts
Call options by funds: $981K | Put options by funds: $185K
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
21.16% more ownership
Funds ownership: 46.63% → 67.79% (+21%)
11% more funds holding
Funds holding: 54 → 60 (+6)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$10.3M |
| 2 |
VA
VR Adviser
New York
|
+$6.9M |
| 3 |
Blackstone Inc
New York
|
+$4.55M |
| 4 |
CC
Commodore Capital
New York
|
+$3.68M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.91M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$1.32M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.27M |
| 4 |
EP
Eversept Partners
New York
|
-$1.01M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$845K |
CABA Hedge Fund Activity: Q4 2022 in Review
60 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q4 2022, worth a combined $183M — up 2,256% from $7.76M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CABA positions and 17 closed out — a net gain of 6 holders — while 12 added to existing stakes and 18 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $10.3M. The largest seller was Renaissance Technologies, cutting an estimated $1.91M.
- 60 institutional investors held Cabaletta Bio (CABA) as of Q4 2022, up from 54 in Q3 2022.
- Funds reported $183M of Cabaletta Bio stock for Q4 2022, up 2,256% quarter-over-quarter.
- 23 funds opened new Cabaletta Bio positions in Q4 2022 and 17 closed out, a net change of +6 holders.
- The largest Cabaletta Bio buyer in Q4 2022 was Lynx1 Capital Management, an estimated $10.3M added.
- The largest Cabaletta Bio seller in Q4 2022 was Renaissance Technologies, an estimated $1.91M sold.
Based on aggregated 13F filings for Q4 2022.